Based on current studies, researchers are encouraged to consider the following points when administering DSIP intranasally: The optimal dosing schedule will depend upon the studys methodology and desired outcome
Elimination is slow so it is recommended to take precautions in patients with severe liver impairment.52 The administration of pioglitazone and rosiglitazone for the treatment of NAFLD (presumably without cirrhosis) with or without DM has yielded conflicting results
As more people start using them, some are talking about the unexpected side effects, including muscle loss and weakness
Clinical trials of semaglutide show average weight loss of 15-22% over 68 weeks, with many patients achieving reductions substantial enough to eliminate sleep apnea entirely
In people whose B12 is already in the normal range, the data is more modest
This offers a degree of precision that can be very advantageous in a research setting